

30. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. *N Engl J Med* 2004; **350**: 1828–1837.
31. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. *Blood* 1998; **92**: 3152–3162.
32. van Imhoff GW, Boerma EJ, van der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. *J Clin Oncol* 2006; **24**: 4135–4142.
33. Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. *J Clin Oncol* 2006; **24**: 961–968.
34. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). *Blood* 2003; **101**: 4279–4284.
35. Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. *Blood* 2006; **107**: 4207–4213.
36. Wilson KS, Sehn LH, Berry B, et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. *Leuk Lymphoma* 2007; **48**: 1102–1109.
37. Nyman H, Adde M, Karjalainen-Lindsberg M-L, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. *Blood* 2007; **109**: 4930–4935.
38. Linderth J, Jerkeman M, Cavallin-Stahl E, et al. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. *Clin Cancer Res* 2003; **9**: 722–728.
39. Tagawa H, Suguro M, Tsuzuki S, et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. *Blood* 2005; **106**: 1770–1777.
40. Yamaguchi M, Nakamura N, Suzuki R, et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. *Haematologica* 2008; **93**: 1195–1202.
41. Ennishi D, Takeuchi K, Yokoyama M, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. *Ann Oncol* 2008; **19**: 1921–1926.
42. Kanda M, Suzumiya J, Ohshima K, Tamura K, Kikuchi M. Intravascular large cell lymphoma: clinicopathological, immuno-histochemical and molecular genetic studies. *Leuk Lymphoma* 1999; **34**: 569–580.
43. Estalilla OC, Koo CH, Brynes RK, Medeiros LJ. Intravascular large B-cell lymphoma; a report of five cases initially diagnosed by bone marrow biopsy. *Am J Clin Pathol* 1999; **112**: 248–255.
44. Yegappan S, Coupland R, Arber DA, et al. Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma. *Mod Pathol* 2001; **14**: 1147–1156.
45. Ito M, Kim Y, Choi JW, Ozawa H, Fujino M. Prevalence of intravascular large B-cell lymphoma with bone marrow involvement at initial presentation. *Int J Hematol* 2003; **77**: 159–163.
46. Murase T, Yamaguchi M, Suzuki R, et al. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. *Blood* 2007; **109**: 478–485.
47. Shimada K, Matsue K, Yamamoto K, et al. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. *J Clin Oncol* 2008; **26**: 3189–3195.
48. Garcia-Suarez J, Banas H, Arribas I, et al. Dose-adjusted EPOCH plus rituximab is an effective regimen in patient with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. *Br J Haematol* 2007; **136**: 276–285.
49. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. *J Clin Oncol* 2008; **26**: 2717–2724.
50. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. *Blood* 2003; **102**: 4284–4289.

## JB Review

# Alternative lengthening of telomeres pathway: Recombination-mediated telomere maintenance mechanism in human cells

Received August 11, 2010; accepted September 29, 2010; published online October 11, 2010

**Akira Nabetani\* and Fuyuki Ishikawa**

Laboratory of Cell Cycle Regulation, Department of Gene Mechanisms, Graduate School of Biostudies, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan

\*Akira Nabetani, Laboratory of Cell Cycle Regulation, Department of Gene Mechanisms, Graduate School of Biostudies, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. Tel: +81 75 753 4196, Fax: +81 75 753 4197, email: anabe@lif.kyoto-u.ac.jp

Unlimitedly proliferating cells need to acquire the telomere DNA maintenance mechanism, to counteract possible shortening through multiple rounds of replication and segregation of linear chromosomes. Most human cancer cells express telomerase whereas the other cells utilize the alternative lengthening of telomeres (ALT) pathway to elongate telomere DNA. It is suggested that ALT depends on the recombination between telomere repetitive DNAs. However, the molecular details remain unknown. Recent studies have provided evidence of special structures of telomere DNA and genes essential for the phenotypes of ALT cells. The molecular models of the ALT pathway should be validated to elucidate recombination-mediated telomere maintenance and promote the applications to anti-cancer therapy.

**Keywords:** alternative lengthening of telomeres (ALT)/extrachromosomal telomeric repeat (ECTR)/PML body/recombination/telomere.


**Abbreviations:** ALT, alternative lengthening of telomeres; BIR, break-induced replication; CDK, cyclin-dependent kinase; DDR, DNA damage response; DSB, double-stranded DNA break; DSBR, double-stranded DNA break repair; HR, homologous recombination; RCR, rolling-circle replication.

Telomeres are specific chromatin structures at the linear chromosome ends of eukaryotic cells. Each telomere contains an end of a double-stranded (ds) DNA, which is protected from degradation and repair processes that can cause chromosome instability. This end protection requires functional telomere chromatin that includes specialized DNA (telomere DNA) and its binding proteins (telomere binding proteins) (Fig. 1A and B). The telomere DNA of most eukaryotes is repetitive DNA containing a guanine-rich (in human, 5'-TTAGGG-3') strand and its complementary strand

called G- and C-strands, respectively. The 3'-end of G-strand extends to form a single-stranded (ss) structure called the G-tail (1). The G-tail is thought to invade and hybridize with the proximal C-strand to form a special structure called the t-loop (2). Shelterin is a conserved protein complex on telomeres, and shelterin in mammalian cells is composed of one ss (POT1) and two ds (TRF1 and TRF2) telomere DNA binding proteins as well as specific proteins to connect those DNA binding proteins (3, 4). This complex serves as the functional framework of telomere chromatin.

Telomere DNA in dividing cells is subject to possible shortening or the so-called end-replication problem (Fig. 1C) (5, 6). Semi-conservative replication cannot complete the syntheses of the very ends of linear DNA. Thus after multiple rounds of cell division, human somatic cells have shortened telomere DNA, which results in irreversible cell growth arrest, namely, replicative senescence (7, 8). On the other hand, cancer cells express certain mechanisms to counteract the shortening of telomere DNA and acquire immortality. Telomerase is a specific reverse transcriptase that elongates the G-strand telomere DNA (9). Approximately 90% of cancer cells maintain telomeres in a telomerase-dependent manner; however, some telomerase-negative human cell lines have been established from cancer cells and *in vitro* immortalized cells (10). Thus, it is imperative to understand both telomerase- and telomerase-independent pathways to inhibit the immortality of cancer cells.

In yeast and mouse, telomerase-negative cells have been directly isolated from 'survivors' after artificial disruption of the gene encoding the telomerase RNA component (telomere RNA: TR) or the catalytic subunit (telomere reverse transcriptase: TERT). Survivors in fission yeast *Schizosaccharomyces pombe* occasionally develop self-circularized chromosomes to circumvent the end-replication problem (11, 12), whereas survivors in other species generally acquire the lengthening mechanism of telomere DNA at linear chromosome ends (Fig. 1D) (13–15). Phenotypic variations among telomerase-negative cells gave birth to the idea that there may be more than one telomerase-independent pathway. One of the most significant examples is the alternative lengthening of telomeres (ALT) pathway of human cells. Confusingly, 'ALT' is sometimes used for various telomerase-independent pathways in human and other species. The ALT we describe here is confined to the pathway found in a group of human telomerase-negative cells (hereafter, ALT cells) showing two distinctive telomere



**Fig. 1** Telomere structure and lengthening. (A) Vertebrate telomere DNA. (B) Shelterin complex in human cells. (C) End-replication problem. The G-strand (red) is completely replicated to the end. However, the C-strand (blue) of telomere DNA is synthesized as a lagging strand and thus the copy of the very end cannot be accomplished. This causes the gradual shortening of telomere DNA through rounds of cell divisions. (D) Two types of telomere lengthening mechanism. The G-strand is primarily elongated in the telomerase pathway (top). Telomerase-independent pathway (bottom) is generally recombination-mediated.

phenotypes; heterogeneous and long telomere DNA and the formation of ALT-associated promyelocytic leukaemia (PML) body (APB). These phenotypes are widely used as convenient markers for ALT cell lines. In this review, we will summarize the characteristics and the most recent findings of the human ALT pathway. We will also discuss the molecular mechanism of ALT and its relevance to diverse telomerase-independent pathways.

### Telomere DNA length and recombination in ALT cells


Telomere DNA length is generally analysed by the Southern hybridization of genomic DNA treated with appropriate restriction enzymes. The mean length of telomere in human telomerase-positive cancer cell lines is usually <10 kb. In contrast, ALT cells have longer and more heterogeneous telomeres; the mean length is ~20 kb (16). This suggests that ALT is a distinct lengthening mechanism from the telomerase pathway and telomere length analysis is regarded as one of the vital tests for ALT. A fluorescent *in situ* hybridization (FISH) experiment of metaphase chromosomes also demonstrated the remarkable heterogeneity of telomere lengths in ALT cells. The signal strengths of the telomere foci in ALT cells varied markedly, whereas those in telomerase-positive cells were comparable between chromosome ends (17). It is unknown how the heterogeneity of telomere lengths developed; however, it may be related to telomere metabolism specific to ALT cells.

The dynamic behaviour of telomere length in ALT cells was described in a study that used cells with artificially tagged telomeres (18). A tag sequence inserted near the telomere repeats of a defined chromosome end was used as a probe to measure the length of this telomere DNA specifically. The telomere in an ALT cell line was drastically elongated during cell division, which differed from that in telomerase-positive cells. The telomeres also showed gradual shortening similar

to normal somatic cells and sometimes exhibited rapid deletion. The rapid changes in the telomere DNA length of this ALT cell line suggest homologous recombination (HR) between telomeres. Another study demonstrated that a tag sequence within the telomere repeats of one chromosome was duplicated to other chromosome ends through cell division in ALT cells but not in telomerase-positive cells (19). This recombination event may reflect the ALT pathway in which telomeres are elongated by making a copy of the telomere DNAs of different chromosomes.

It is possible that ALT cells represent elevated levels of HR at other loci as well as telomere repeats. The instability of the repetitive sequences of minisatellites was more frequently noted in ALT cell lines than in telomerase-positive cell lines (20, 21). However, ALT-specific hyper-recombination was not observed when the frequencies of intrachromosomal recombination were analysed by using a reporter construct integrated into a certain chromosome locus (22). Therefore, ALT cells may have the feature of elevated recombination only in the loci with repetitive sequences, such as telomeres and minisatellites.

To visualize *de novo* synthesized telomeric G- or C-strand specifically, chromosome orientation (CO)-FISH analysis was applied to telomeres (Fig. 2). In metaphase chromosomes, the CO-FISH signal was typically observed at the telomere of either one of the sister chromatids. The frequencies of telomere-sister-chromatid exchange (T-SCE) were calculated as the percentage of chromosome ends positive for CO-FISH signals on both sister telomeres. The high level of T-SCE was generally found in ALT but not in telomerase-positive cells (23–25) and therefore, hyper-recombination between sister telomeres was recognized as one of the features of ALT cells. However, T-SCE or the reciprocal exchange of sister telomeres by itself does not accompany massive DNA synthesis and could not account for the net elongation of telomeres or the ALT pathway.



**Fig. 2 CO-FISH analysis and T-SCE.** (A) Outline of CO-FISH method. The nascent DNA strands (pale blue) are labeled with BrdU and BrdC and they can be specifically degraded. The template strands are exposed and can be hybridized with the fluorescent G- or C-probe (green or red bar). The signal of each probe can be observed at telomere of each one of sister chromatids. (B) Observation of T-SCE by CO-FISH. When T-SCE is occurred after DNA replication, the signals of CO-FISH can be observed at the both sister telomeres.

### Particular structures of telomere DNA in ALT cells


The first evidence of unusual telomere DNA in ALT cells is the extrachromosomal telomere repeat (ECTR). FISH analyses of metaphase chromosomes of ALT cells suggested the presence of significant telomere DNA repeats other than the chromosome ends (26). ALT cells harbour small ds linear telomere DNA in the soluble fractions of the cell extract, which can be separated from bulk chromatin (27). Circular DNA molecules were occasionally found in ALT cells by electron microscopy and these are thought to correspond to the circular form of telomere DNA (t-circle) determined by two-dimensional (2D) gel electrophoresis (28, 29). T-circles are now regarded as a marker for ALT cells, although they can be observed in telomerase-positive cells that have a defect in TRF2 or that contain extensively elongated telomere DNA (29, 30). T-circles can be produced by the intrachromosomal recombination

of telomere repeats (Fig. 3A). ALT cells may acquire a feature that induces such recombination events.

ALT cells harbour in particular ss structures of telomere DNA (31). The average lengths of ss telomere DNA are shorter than those of ds telomere DNA, suggesting that telomere in ALT cells contains nicked and/or gapped structures. Different forms of ss telomere DNA were resolved by 2D gel electrophoresis. The small sized ones of G- and C-strands were separated in the electrophoresis and showed the different sensitivities to structure-specific nucleases: the single G-strand structure (ss-G) was concluded to be linear DNA whereas the single C-strand structure (ss-C) was circular DNA. A sensitive method to detect circular C-strands was developed and applied to examine various cell lines (32). Interestingly, ALT cell lines were positive for the circular C-strands whereas telomerase-positive cells were negative. This suggests that this 'C-circle (CC) assay' is useful to determine whether the tested cancer cells are ALT or not. In addition, branched molecules of telomere DNA were found in the ss telomere structures of ALT cells. These remarkable structures of telomere DNA, t-circles and various ss structures, must be specific intermediates or crucial substrates for telomere metabolism in the ALT pathway.

The ALT pathway must be mediated by some HR-based mechanism where the nascent telomere DNA is synthesized efficiently. That is, the ALT pathway could induce pairing of the G- and C-strands *in trans* by HR to form the primer and the template. DNA synthesis should follow to elongate telomere DNA from the primer. One possible mechanism is break-induced replication (BIR). In BIR, the 3'-end of ss DNA invades a region with a homologous sequence at first, and then DNA synthesis is initiated at the 3'-end by using the paired strand as template. It has been suggested that BIR must operate in the telomere lengthening in ALT cells (Fig. 3B). When the 3'-end of the G-tail is paired with the C-strand of other telomeres, a nascent G-strand can be synthesized and elongated up to the end of the template C-strand. BIR readily accounts for the high frequency of copy of a tag in telomere DNA (19), although the function of circular telomere DNA specifically found in ALT cells (t-circle and ss-C) is unclear.

The integration of t-circles into the telomere repeats at chromosome ends will result in telomere elongation (Fig. 3C). However, it does not increase the net amount of telomere DNA in the cells and cannot complete telomere maintenance through multiple divisions of ALT cells. Furthermore, circular forms of DNA can be involved in the rapid elongation of DNA ends in rolling-circle replication (RCR) (Fig. 3D). When the 3'-end of the G-tail is paired with ss-C and/or t-circles in ALT cells, the synthesis of the G-strand can be induced on this circular DNA as a template. RCR is fundamentally a continuous process and can accomplish very efficient lengthening even with small templates. Interestingly, the ss-G structure in ALT cells is similar to the linear ss intermediates of RCR in yeast mitochondria DNA (33). BIR and RCR are not exclusive of each other and both require invasion



**Fig. 3 Telomere DNA metabolism in ALT cells.** Four types of recombination events result in particular DNA metabolisms and unique products. (A) Recombination within t-loop causes rapid telomere shortening and t-circle formation. (B) Recombination between telomeres of chromosome ends initiates break-induced replication. (C) Transfer of a strand of t-circle into telomeres at chromosomal DNA initiates elongation of the repetitive DNA. (D) Invasion of t-circle by G-tail triggers rolling-circle replication.

of the 3'-end of the G-tail with the C-strand and the initiation of DNA synthesis at the pairing sites. This implies that both mechanisms may contribute to the ALT pathway and be regulated by common molecular mechanisms.

### ALT-associated PML body

PML body is a nuclear aggregate of PML and other proteins and is insensitive to low concentration of non-ionic detergent. PML bodies are present in many types of cells, *e.g.* in both telomerase-positive and ALT cell lines. It has been suggested that PML body functions in various cellular processes, including tumour formation, cellular senescence, stress response, DNA repair, etc. However, its molecular function(s) remains unsolved. Although PML bodies are usually unrelated to telomere, many telomerase-negative cell lines commonly have ALT-associated PML body (APB), a special form of PML body that includes telomere DNA and chromatin (34). This feature, namely, the colocalization of both markers for telomere and PML body, can be readily observed and thus, the formation of APB has been used as a marker for ALT cells. Although it is unknown how APBs are related to the ALT pathway, it is noteworthy that APBs possess a variety of proteins working in DNA metabolism and cell growth regulation (Table I). The localization of recombination proteins at APBs supports the idea that HR may be associated with ALT.

The incorporation of the thymidine analogue bromodeoxyuridine (BrdU) was observed in a fraction of APBs (35). This nascent DNA synthesis at APBs was suppressed by inhibitors of ATM and ATR (36), which are members of phosphoinositide 3-kinase related kinase (PIKK) crucial for the activation of DNA-damage response (DDR). This suggests that the ALT pathway may be regulated by damage signaling. Telomeres of ALT cells are colocalized with the markers for DDR, for example,  $\gamma$ -H2AX, 53BP1, the

RAD9-RAD1-HUS1 (9-1-1) complex, and its loader RAD17 (36, 37). However, it is unknown whether DDR of telomere in ALT cells is activated by particular ss structures of telomere DNA. Two reports suggested that APBs have a special form of telomere DNA. The major telomere DNA components in APB are chromosome ends; thus the chromosome ends may cluster at APBs to enhance HR between telomeres (38). In contrast, purification study suggests that APBs predominantly contain linear ECTRs (39). Therefore, the specific structures of telomere DNA in APBs and their relevance to the ALT pathway have still to be unraveled.

### Proteins required by ALT cells

To elucidate the molecular mechanism of the ALT pathway, phenotypes of ALT cells were examined when the function of proteins and/or the expression of their coding genes were suppressed or induced (Table I). The candidate proteins of interest were the components of telomere chromatin, APB and DNA metabolisms including HR. Among the phenotypes, changes in telomere length were particularly notable in the analyses. The erosion of telomere DNA from ALT cells may be due to two reasons: one is a defect in the ALT pathway or the lengthening mechanism of telomere DNA. This will gradually reduce telomere lengths as the end-replication problem emerges. The other is the imperfect protection of telomere. As telomere DNA in ALT cells contains remarkable ss and/or branched structures, ALT cells may be sensitive to even small damages in the telomere DNA caused by certain gene mutations or overexpression. The defect may cause the sudden loss of telomere. In both cases, a shortened telomere DNA is expected to induce defects in cell growth and/or cellular senescence. In addition, ALT-specific phenotypes, for example, the formation of APB and the frequency of T-SCE, were also examined.

Table I. Proteins related to ALT pathway.

Name	Tests <sup>a</sup>	Remarks	References
53BP1	LK	DDR	(37, 43)
ATM	L	DDR; PIKK	(46)
ATR	LK	DDR; PIKK	(57)
BLM	LK	DSBR; RecQ-like helicase	(47, 48, 70)
BRCA1	L	HR; breast cancer 1	(71)
Cdk2	L	Cell cycle; CDK	(58)
COUP-TF1	L	Unknown; orphan nuclear receptor	(59)
COUP-TF2	L	Unknown; orphan nuclear receptor	(59)
ERCC1	L	Excision repair; endonuclease	(72)
FANCA	K	DSBR	(57)
FANCD2	LK	DSBR	(57)
FANCF	L	DSBR; structure-specific DNA helicase	(59)
FANCL	K	DSBR; E3 ubiquitin ligase	(57)
FEN1	K	Replication; flap endonuclease	(55)
$\gamma$ -H2AX	L	DSB marker; phosphorylated H2AX	(36, 37)
hnRNP A2	L	Regulator of splicing; hnRNP	(73)
HUS1	L	DDR; 9-1-1 PCNA-like clamp	(36)
HP1 $\alpha$	LK	Heterochromatin	(58)
HP1 $\beta$	LK	Heterochromatin	(58)
HP1 $\gamma$	LK	Heterochromatin	(58)
HSP90	L	Heat shock protein	(47)
MDC1	L	DDR	(37)
MMS21	LK	DDR; E3 SUMO ligase in SMC5/6	(41)
MRE11	LK	HR; MRN complex subunit	(42, 43, 74)
MUS81	LK	HR; structure-specific endonuclease	(53)
NBS1	LK	HR; MRN complex subunit	(42, 43, 74)
NXP2	L	PML body	(59)
p21	LK	Regulator of growth; CDK inhibitor	(58)
p53	LE <sup>b</sup>	Tumour suppression; transcription factor	(46, 58)
PARP2	L	DSBR; poly (ADP-ribose) polymerase	(75)
PCNA	LK	Replication; clamp	(58)
PML	LK	PML body	(34, 43)
POT1	L	Shelterin; ss telomere DNA binding	(48)
RAD1	L	DDR; 9-1-1 PCNA-like clamp	(36)
RAD9	L	DDR; 9-1-1 PCNA-like clamp	(36)
RAD17	L	DDR; chromatin loader for 9-1-1 clamp	(36)
RAD50	LK	HR; MRN complex subunit	(41–43, 74)
RAD51	LK	HR; RecA-like, strand exchange protein	(34, 41)
RAD51D	LK	HR; resolution of Holliday junction	(54)
RAD52	L	HR; DNA binding protein	(34)
RAP1	LK	Shelterin; TRF2-interacting	(43, 71)
RIF1	L	DDR	(76)
RIP140	L	Transcription; co-regulator	(59)
RPA32	LK	Replication and HR; ss DNA binding	(56)
RPA70	LK	Replication and HR; ss DNA binding	(56)
SMC5	LK	DDR; structural maintenance complex	(41)
SMC6	L	DDR; structural maintenance complex	(41)
Sp-100	LKE	PML body	(40, 43, 71)
STN1	L	Telomere; ss DNA binding CST complex	(77)
TEP1	L	Telomere	(47)
TF4	L	Unknown; orphan nuclear receptor	(59)
TIN2	LK	Shelterin	(43, 48)

(continued)

Table I. Continued

Name	Tests <sup>a</sup>	Remarks	References
TopoII $\alpha$	L	DNA structure; topoisomerase, type II	(47)
TopoIII $\alpha$	LK	DNA structure; topoisomerase, type IA	(48)
TRF1	LK	Shelterin; ds telomere DNA binding	(34, 43)
TRF2	LK	Shelterin; ds telomere DNA binding	(34, 43, 46)
WRN	LK	HR; RecQ-like helicase and nuclease	(78, 79)
XPF	L	Excision repair; endonuclease	(72)
XRCC3	K	HR, resolution of Holliday junction	(44)

<sup>a</sup>L, localization at telomeres in ALT cells; K, knockdown of gene; E, ectopic expression of protein.

<sup>b</sup>Activation of p53 by RNAi of SV40 large T-antigen.

### MRN complex

The MRN complex, which includes MRE11, RAD50 and NBS1, functions in the early steps of HR and ds DNA break (DSB) repair (DSBR). Interestingly, this complex constitutes APB and the homologous complex in budding yeast plays essential roles in the telomerase-independent telomere lengthening mechanism (see below). Overexpression of Sp-100, a component of PML body that can interact with NBS1, inhibited the proper localization of NBS1 to APBs. This sequestration of NBS1 from APBs or the knockdown of each of MRN gene induced the shortening of telomere DNA in ALT cells (40–42). MRN was also required for APB formation (43). The knockdown of the gene encoding RAD50 or the overexpression of Sp-100 caused a significant reduction of t-circles (32, 44), suggesting the function of MRN in the maintenance of ALT-specific telomere DNA.

### TRF2 and shelterin

TRF2 is a ds telomere DNA binding protein in the shelterin complex, which is essential for end protection. A defect in TRF2 stimulates chromosome fusion between telomeres in telomerase-positive cells (45). U2-OS is an ALT cell line established from human osteosarcoma, which is expressing wild-type p53 and Rb, but lacking p16. The phenotypes of U2-OS were examined after inhibition of TRF2 by siRNA or the expression of the dominant-negative form of the protein (46). Telomere DNA of TRF2-deficient U2-OS cells was shortened and the cells expressed  $\beta$ -galactosidase activity similar to senescent cells. The significant activation of p53 and p21 observed in those cells was dependent on PML protein, a major component of APB. The formation of APB was not affected in TRF2-deficient cells, although another report showed that four of six shelterin components, TRF1, TRF2, TIN2 and RAP1, were required for APB formation (43).

### RecQ-like DNA helicases

DNA helicases of the RecQ family act on atypical DNA structures, such as intermediates of HR, stalled

sites of replication forks and the G-quartet structure of telomere DNA. This function is important for genome integrity; mutations in either one of the three genes encoding RecQ-like DNA helicases in human, *BLM* (Bloom syndrome), *WRN* (Werner syndrome) or *RECQL4* (Rothmund–Thomson's syndrome, RTS), cause chromosome abnormality and premature aging. *BLM* is an APB protein and the knockdown of the gene induces rapid shortening of telomere DNA and inhibition of ALT cell growth (47, 48). *BLM* forms a functional complex with topoisomerase III $\alpha$  (TopoIII $\alpha$ ) to suppress HR (49). Knockdown of the TopoIII $\alpha$  gene in ALT cells also resulted in the loss of the G-tail, chromosome bridges or fusions of sister telomeres at anaphase, and cell growth retardation (48). The phenotypes of TopoIII $\alpha$ -knockdown cells could be due to indirect effects as the amounts of *BLM* and TRF2 were concurrently decreased.

*WRN* is also localized at APB, although it seems to be dispensable for ALT cells. When fibroblasts mutated in *WRN* from a Werner syndrome patient were immortalized with SV40, a cell line that utilizes the ALT pathway to maintain the telomere DNA was established (50, 51). In mouse, the survivors of *Wrn* (encodes *WRN* homologue) *Terc* (TR) double knock-out were obtained and they showed elevated levels of T-SCE as in human ALT cells (52). These results suggest that ALT (human) and a telomerase-independent lengthening mechanism (mouse) can be activated without the function of *WRN*.

#### Resolution of Holliday junction

A striking intermediate of HR is the Holliday junction, a cruciform structure formed by two ds DNAs (Fig. 4). ALT cells show elevated T-SCE and contain branched structures in telomere DNA, so that they may require efficient resolution of the junction. *MUS81* and its interacting protein *MMS4* together constitute endonuclease specific to unpaired ds DNA, for example, the Holliday junction. The knockdown of *MUS81* in ALT cells caused growth arrest, loss of telomeres on metaphase chromosomes, and reduced frequency of T-SCE (53). The ectopic expression of TERT complemented the suppression of cell growth, but not the low T-SCE frequency. Interestingly, the length of telomere DNA and the amount of t-circles from Southern analyses were not altered in *MUS81* knockdown cells. It is unknown how telomere loss from chromosome ends is induced without a significant reduction in telomere length.

*XRCC3*, a *RAD51*-paralog that is presumably involved in the resolution of the Holliday junction, is required for the maintenance of t-circles (44). *RAD51D*, another *RAD51*-paralogue for the resolution, is an APB protein and its inhibition led to shortened telomere DNA and chromosome bridges (54). These *RAD51*-paralogues must be required for HR of telomere DNA in ALT cells. *RAD51*, which plays a central role in strand transfer in HR rather than the resolution of the Holliday junction, was not crucial for APB formation (41). It remains unknown whether *RAD51* functions in the HR of telomere DNA and the ALT pathway.




Fig. 4 Formation and resolution of the Holliday junction. The reciprocal exchange between two ds DNA (top, red/blue and pink/pale blue) is shown. The Holliday junction (middle) is a cruciform DNA formed in HR, and the resolution (bottom) requires cut and ligation at the junction.

#### Other proteins in DNA metabolism

*FEN1* is a flap endonuclease that processes the 5'-end of Okazaki fragment to assist the completion of the lagging-strand synthesis. The homologue of *FEN1* in budding yeast plays a role in the processing of the C-strand of telomere DNA. *FEN1*-deficient ALT cells showed elevated levels of DDR at telomeres (55). This response was suppressed by the ectopic expression of TERT. RPA is a conserved trimeric protein complex essential for replication and recombination. Two subunits of RPA, RPA32 and RPA70, are localized at APB, and the knockdown of either one of them in ALT cells resulted in ss G-strand accumulation and cell growth arrest (56). It needs to be clarified how crucial these replication proteins are for the telomere maintenance in ALT cells.

#### Sumoylation and ubiquitination

The PML body generally concentrates small ubiquitin-like modifier (SUMO) and proteins required for sumoylation. The first evidence of the function of sumoylation in ALT and APB was provided by a work on the SMC5/6 complex (41). SMC5/6, which is one of the structural maintenance of chromosomes (SMC) complexes in eukaryotes, plays important roles in DNA repair and DDR. The complex includes *MMS21*, a specific E3 SUMO ligase, as a non-SMC subunit. SMC5/6 and *MMS21* are APB components and the knockdown of each of the genes caused reduced numbers of APBs in a cell. The knockdown of *SMC5* or *MMS21* in ALT cells induced telomere DNA shortening, telomere DNA loss at chromosome termini, cell growth suppression and  $\beta$ -galactosidase activity expression as in senescent cells. Meanwhile,

telomere DNA shortening and cell growth inhibition were not observed in SMC5- or MMS21-deficient telomerase-positive cells, suggesting their specific function in telomere maintenance and cell growth in ALT cells. MMS21 was able to sumoylate at least four shelterin proteins, TRF1, TRF2, TIN2 and RAP1. Mutated TRF1 at its sumoylated site abolished the localization at APB, suggesting that the sumoylation of the telomere binding proteins regulates APB formation.

FANC proteins were originally identified from mutated genes in patients with the genetic disease Fanconi anemia, whose cells commonly show chromosomal abnormality. The localization of FANCD2 at APBs required the function of FANCA and FANCL, both of which are essential for the monoubiquitination of FANCD2 (57). The knockdown of the gene encoding FANCD2 or FANCA induced telomere loss and T-SCE reduction in ALT cells. In DDR, the monoubiquitination of FANCD2 and the formation of FANCD2 nuclear foci required ATR kinase. Interestingly, the localization of FANCD2 at APB was also dependent on ATR. These suggest that FANCD2 may be regulated by ATR-dependent monoubiquitination for its proper localization and function on telomere in ALT cells.

#### Other factors related to ALT pathway

Tumour suppressor p53 is a crucial regulator of genome stability. Human p53 is localized at APB in ALT cells; however, it is not necessary for APB formation (46). In an ALT cell line established by the transformation with the T antigen of SV40, p53 was activated by the knockdown of the T antigen gene. APBs of those cells were enlarged (58), suggesting that p53 is a positive regulator of APB formation. This effect is dependent on the function of p21 and heterochromatin protein HP1, both of which are also APB components.

Several novel APB proteins were identified using a unique purification method to concentrate chromatin proteins associated with telomere DNA (59). The inhibition of COUP-TF2, a novel APB protein and an orphan nuclear receptor, caused a defect in APB formation and the shortening of telomere DNA. The molecular function of those novel APB proteins in the ALT pathway remains to be elucidated.

The phenotypes of ALT cells were suppressed in hybrid cell lines of ALT and telomerase-positive cells (60). This suggests that ALT cells may have some recessive mutations in gene(s) required for the inhibition of the ALT pathway. The genes proposed in that study have not been identified; nevertheless, they are expected to provide some hints for the ALT regulation mechanism. The coexistence of ALT and the lengthening by telomerase was apparently observed (17), indicating that telomerase activity alone is not sufficient to suppress the ALT phenotypes. This also suggests that some telomerase-positive cancer cells may activate the ALT pathway at the same time.

#### Similarities in telomerase-independent lengthening mechanisms

Cells that develop telomerase-independent lengthening mechanisms have been providing valuable hints for the ALT pathway. In the case of budding yeast *Saccharomyces cerevisiae* and its related species, survivors were recovered from cells with a disrupted TR gene and classified into two groups: type I cells have amplified subtelomeric DNA and depend on Rad51, and type II cells have elongated telomere repeats and require the function of MRX (MRN homologue) (61, 62). As type II yeast cells and ALT cells have elongated telomere repeats, it is thought that these pathways depend on a conserved mechanism. It is significant that both human RAD51 and MRN are localized at APBs, suggesting that both of them are related to the ALT pathway. It is unknown whether the ALT pathway is made up of subpathways, as in types I and II cells of budding yeast.

As in human ALT cells, budding yeast type II cells harbour t-circles. When a model circular telomere DNA was introduced into type II cells, this DNA was copied to chromosome ends to form a tandem array (63–65). These results can be explained by RCR, in which the model circular DNA is utilized as a template for amplification. RCR may also play a crucial role in the replication of the linear mitochondrial DNA of the yeast *Candida parapsilosis*. Replication intermediates of the ends of mitochondrial DNA include a strand-specific ss DNA structure (33) that is commonly observed in RCR. These findings imply that RCR may be a conserved and general mechanism for the telomerase-independent pathway in eukaryotes.

The mouse knockout mutant of any genes of interest is one of the best model systems for human biology. Survivor cells from *Terc* (TR)<sup>-/-</sup> apparently maintained their telomere DNA in a telomerase-independent manner. In a cell line established from *Terc*<sup>-/-</sup> embryonic stem (ES) cells, the tandem arrays of telomeric and non-telomeric sequences were observed at the chromosome ends (66). Interestingly, most of the chromosome ends contained the same arrays. This suggests that these cells can amplify the arrays to maintain the chromosome ends. An array of this unique sequence was possibly built at one chromosome end at first, and then it expanded to the other chromosome ends. In an example of a human telomerase-negative cell line, the array of telomeric and ectopic DNA sequences (derived from SV40 DNA) was attached to most of the chromosome ends (50, 51). These cells harboured circular extrachromosomal DNA that includes the similar sequence to the array at the chromosome ends, suggesting that the circular DNAs may be analogous to t-circles in ALT cells. It is interesting to examine whether the circular episome is required for the lengthening of the chromosome ends in these cells. Another survivor cell line from *Terc*<sup>-/-</sup> mouse embryonic fibroblasts showed heterogeneous telomere DNA lengths and the formation of APBs (67). This would serve as an invaluable



model system for the human ALT pathway and cancer development.

The ES cells from knockout mice mutated in DNA methyltransferase genes showed frequent T-SCE and APB formation, even though the cell lines were positive for telomerase activity (68). DNA hypomethylation at the subtelomere region was observed in those cells. This suggests that the epigenetic state of the cells may affect the frequency of T-SCE and APB formation. In human ALT cells, on the other hand, the relationship between the methylation status at the subtelomere region and T-SCE frequency was less clear (69).

### Conclusions

Several lines of evidence strongly suggest that the ALT pathway is dependent on HR. First, a DNA fragment in the telomere repeats of chromosome ends can be copied into the ends of different chromosomes in ALT cells. Second, several kinds of proteins essential for HR are localized at APB. Third, a defect in some HR proteins induces erosion of telomere DNA in ALT cells. Lastly, the unique structures of telomere DNA found in ALT cells, such as ss telomere DNA and circular ECTR, may represent the intermediates and/or substrates of the elongation mechanisms based on HR. Importantly, the similar telomere DNA structures are also observed in cells that utilize HR-mediated telomere maintenance in other organisms. For the further elucidation of the ALT pathway, it is essential to establish a model experiment system in order to acquire direct evidence of the mechanism of HR-dependent telomere elongation.

### Acknowledgements

We are grateful to the every member of our laboratory for helpful discussions, technical assistance or secretarial work.

### Funding

Research in the authors' laboratory was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; by a Grant-in-Aid for Scientific Research from the MEXT, Japan; and by a grant for Research on Human Genome Tailor-made from the Ministry of Health, Labor, and Welfare, Japan.

### Conflict of interest

None declared.

### References

- Wellinger, R.J., Wolf, A.J., and Zakian, V.A. (1993) Saccharomyces telomeres acquire single-strand TG1-3 tails late in S phase. *Cell* **72**, 51–60
- Griffith, J.D., Comeau, L., Rosenfield, S., Stansel, R.M., Bianchi, A., Moss, H., and de Lange, T. (1999) Mammalian telomeres end in a large duplex loop. *Cell* **97**, 503–514
- de Lange, T. (2005) Shelterin: the protein complex that shapes and safeguards human telomeres. *Genes Dev.* **19**, 2100–2110
- Miyoshi, T., Kanoh, J., Saito, M., and Ishikawa, F. (2008) Fission yeast Pot1-Tpp1 protects telomeres and regulates telomere length. *Science* **320**, 1341–1344
- Olovnikov, A.M. (1973) A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. *J. Theor. Biol.* **41**, 181–190
- Watson, J.D. (1972) Origin of concatemeric T7 DNA. *Nat. New Biol.* **239**, 197–201
- Harley, C.B., Futcher, A.B., and Greider, C.W. (1990) Telomeres shorten during ageing of human fibroblasts. *Nature* **345**, 458–460
- Hayflick, L. and Moorhead, P.S. (1961) The serial cultivation of human diploid cell strains. *Exp. Cell Res.* **25**, 585–621
- Greider, C.W. and Blackburn, E.H. (1985) Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. *Cell* **43**, 405–413
- Bryan, T.M., Englezou, A., Dalla-Pozza, L., Dunham, M.A., and Reddel, R.R. (1997) Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. *Nat. Med.* **3**, 1271–1274
- Naito, T., Matsuura, A., and Ishikawa, F. (1998) Circular chromosome formation in a fission yeast mutant defective in two ATM homologues. *Nat. Genet.* **20**, 203–206
- Nakamura, T.M., Cooper, J.P., and Cech, T.R. (1998) Two modes of survival of fission yeast without telomerase. *Science* **282**, 493–496
- Blasco, M.A., Lee, H.W., Hande, M.P., Samper, E., Lansdorp, P.M., DePinho, R.A., and Greider, C.W. (1997) Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. *Cell* **91**, 25–34
- Lundblad, V. and Szostak, J.W. (1989) A mutant with a defect in telomere elongation leads to senescence in yeast. *Cell* **57**, 633–643
- Yuan, X., Ishibashi, S., Hatakeyama, S., Saito, M., Nakayama, J., Nikaido, R., Haruyama, T., Watanabe, Y., Iwata, H., Iida, M., Sugimura, H., Yamada, N., and Ishikawa, F. (1999) Presence of telomeric G-strand tails in the telomerase catalytic subunit TERT knockout mice. *Genes Cells* **4**, 563–572
- Bryan, T.M., Englezou, A., Gupta, J., Bacchetti, S., and Reddel, R.R. (1995) Telomere elongation in immortal human cells without detectable telomerase activity. *EMBO J.* **14**, 4240–4248
- Perrem, K., Colgin, L.M., Neumann, A.A., Yeager, T.R., and Reddel, R.R. (2001) Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. *Mol. Cell Biol.* **21**, 3862–3875
- Murnane, J.P., Sabatier, L., Marder, B.A., and Morgan, W.F. (1994) Telomere dynamics in an immortal human cell line. *EMBO J.* **13**, 4953–4962
- Dunham, M.A., Neumann, A.A., Fasching, C.L., and Reddel, R.R. (2000) Telomere maintenance by recombination in human cells. *Nat. Genet.* **26**, 447–450
- Jeyapalan, J.N., Varley, H., Foxon, J.L., Pollock, R.E., Jeffreys, A.J., Henson, J.D., Reddel, R.R., and Royle, N.J. (2005) Activation of the ALT pathway for telomere maintenance can affect other sequences in the human genome. *Hum. Mol. Genet.* **14**, 1785–1794
- Tsutsui, T., Kumakura, S., Tamura, Y., Tsutsui, T.W., Sekiguchi, M., Higuchi, T., and Barrett, J.C. (2003) Immortal, telomerase-negative cell lines derived from a Li-Fraumeni syndrome patient exhibit telomere length variability and chromosomal and minisatellite instabilities. *Carcinogenesis* **24**, 953–965

22. Bechter, O.E., Zou, Y., Shay, J.W., and Wright, W.E. (2003) Homologous recombination in human telomerase-positive and ALT cells occurs with the same frequency. *EMBO Rep.* **4**, 1138–1143
23. Bailey, S.M., Brenneman, M.A., and Goodwin, E.H. (2004) Frequent recombination in telomeric DNA may extend the proliferative life of telomerase-negative cells. *Nucleic Acids Res.* **32**, 3743–3751
24. Bechter, O.E., Shay, J.W., and Wright, W.E. (2004) The frequency of homologous recombination in human ALT cells. *Cell Cycle* **3**, 547–549
25. Londoño-Vallejo, J.A., Der-Sarkissian, H., Cazes, L., Bacchetti, S., and Reddel, R.R. (2004) Alternative lengthening of telomeres is characterized by high rates of telomeric exchange. *Cancer Res.* **64**, 2324–2327
26. Tokutake, Y., Matsumoto, T., Watanabe, T., Maeda, S., Tahara, H., Sakamoto, S., Niida, H., Sugimoto, M., Ide, T., and Furuichi, Y. (1998) Extra-chromosomal telomere repeat DNA in telomerase-negative immortalized cell lines. *Biochem. Biophys. Res. Commun.* **247**, 765–772
27. Ogino, H., Nakabayashi, K., Suzuki, M., Takahashi, E., Fujii, M., Suzuki, T., and Ayusawa, D. (1998) Release of telomeric DNA from chromosomes in immortal human cells lacking telomerase activity. *Biochem. Biophys. Res. Commun.* **248**, 223–227
28. Cesare, A.J. and Griffith, J.D. (2004) Telomeric DNA in ALT cells is characterized by free telomeric circles and heterogeneous t-loops. *Mol. Cell Biol.* **24**, 9948–9957
29. Wang, R.C., Smogorzewska, A., and de Lange, T. (2004) Homologous recombination generates T-loop-sized deletions at human telomeres. *Cell* **119**, 355–368
30. Pickett, H.A., Cesare, A.J., Johnston, R.L., Neumann, A.A., and Reddel, R.R. (2009) Control of telomere length by a trimming mechanism that involves generation of t-circles. *EMBO J.* **28**, 799–809
31. Nabetani, A. and Ishikawa, F. (2009) Unusual telomeric DNAs in human telomerase-negative immortalized cells. *Mol. Cell Biol.* **29**, 703–713
32. Henson, J.D., Cao, Y., Huschtscha, L.I., Chang, A.C., Au, A.Y., Pickett, H.A., and Reddel, R.R. (2009) DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. *Nat. Biotechnol.* **27**, 1181–1185
33. Nosek, J., Rycovska, A., Makhov, A.M., Griffith, J.D., and Tomaska, L. (2005) Amplification of telomeric arrays via rolling-circle mechanism. *J. Biol. Chem.* **280**, 10840–10845
34. Yeager, T.R., Neumann, A.A., Englezou, A., Huschtscha, L.I., Noble, J.R., and Reddel, R.R. (1999) Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. *Cancer Res.* **59**, 4175–4179
35. Grobely, J.V., Godwin, A.K., and Broccoli, D. (2000) ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle. *J. Cell Sci.* **113**(Pt 24), 4577–4585
36. Nabetani, A., Yokoyama, O., and Ishikawa, F. (2004) Localization of hRad9, hHus1, hRad1, and hRad17 and caffeine-sensitive DNA replication at the alternative lengthening of telomeres-associated promyelocytic leukemia body. *J. Biol. Chem.* **279**, 25849–25857
37. Cesare, A.J., Kaul, Z., Cohen, S.B., Napier, C.E., Pickett, H.A., Neumann, A.A., and Reddel, R.R. (2009) Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions. *Nat. Struct. Mol. Biol.* **16**, 1244–1251
38. Draskovic, I., Arnoult, N., Steiner, V., Bacchetti, S., Lomonte, P., and Londoño-Vallejo, A. (2009) Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination. *Proc. Natl. Acad. Sci. USA* **106**, 15726–15731
39. Fasching, C.L., Neumann, A.A., Muntoni, A., Yeager, T.R., and Reddel, R.R. (2007) DNA damage induces alternative lengthening of telomeres (ALT) associated promyelocytic leukemia bodies that preferentially associate with linear telomeric DNA. *Cancer Res.* **67**, 7072–7077
40. Jiang, W.Q., Zhong, Z.H., Henson, J.D., Neumann, A.A., Chang, A.C., and Reddel, R.R. (2005) Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of the MRE11/RAD50/NBS1 complex. *Mol. Cell Biol.* **25**, 2708–2721
41. Potts, P.R. and Yu, H. (2007) The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins. *Nat. Struct. Mol. Biol.* **14**, 581–590
42. Zhong, Z.H., Jiang, W.Q., Cesare, A.J., Neumann, A.A., Wadhwa, R., and Reddel, R.R. (2007) Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres. *J. Biol. Chem.* **282**, 29314–29322
43. Jiang, W.Q., Zhong, Z.H., Henson, J.D., and Reddel, R.R. (2007) Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. *Oncogene* **26**, 4635–4647
44. Compton, S.A., Choi, J.H., Cesare, A.J., Ozgür, S., and Griffith, J.D. (2007) Xrcc3 and Nbs1 are required for the production of extrachromosomal telomeric circles in human alternative lengthening of telomere cells. *Cancer Res.* **67**, 1513–1519
45. van Steensel, B., Smogorzewska, A., and de Lange, T. (1998) TRF2 protects human telomeres from end-to-end fusions. *Cell* **92**, 401–413
46. Stagno D'Alcontres, M., Mendez-Bermudez, A., Foxon, J.L., Royle, N.J., and Salomoni, P. (2007) Lack of TRF2 in ALT cells causes PML-dependent p53 activation and loss of telomeric DNA. *J. Cell Biol.* **179**, 855–867
47. Bhattacharyya, S., Keirse, J., Russell, B., Kavecansky, J., Lillard-Wetherell, K., Tahmaseb, K., Turchi, J.J., and Groden, J. (2009) Telomerase-associated protein 1, HSP90, and topoisomerase IIalpha associate directly with the BLM helicase in immortalized cells using ALT and modulate its helicase activity using telomeric DNA substrates. *J. Biol. Chem.* **284**, 14966–14977
48. Temime-Smaali, N., Guittat, L., Wenner, T., Bayart, E., Douarre, C., Gomez, D., Giraud-Panis, M.J., Londoño-Vallejo, A., Gilson, E., Amor-Guérét, M., and Riou, J.F. (2008) Topoisomerase IIIalpha is required for normal proliferation and telomere stability in alternative lengthening of telomeres. *EMBO J.* **27**, 1513–1524
49. Wu, L. and Hickson, I.D. (2003) The Bloom's syndrome helicase suppresses crossing over during homologous recombination. *Nature* **426**, 870–874
50. Fasching, C.L., Bower, K., and Reddel, R.R. (2005) Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies. *Cancer Res.* **65**, 2722–2729
51. Marciniak, R.A., Cavazos, D., Montellano, R., Chen, Q., Guarente, L., and Johnson, F.B. (2005) A novel telomere structure in a human alternative lengthening of telomeres cell line. *Cancer Res.* **65**, 2730–2737
52. Laud, P.R., Multani, A.S., Bailey, S.M., Wu, L., Ma, J., Kingsley, C., Lebel, M., Pathak, S., DePinho, R.A., and Chang, S. (2005) Elevated telomere-telomere

- recombination in WRN-deficient, telomere dysfunctional cells promotes escape from senescence and engagement of the ALT pathway. *Genes Dev.* **19**, 2560–2570
53. Zeng, S., Xiang, T., Pandita, T.K., Gonzalez-Suarez, I., Gonzalo, S., Harris, C.C., and Yang, Q. (2009) Telomere recombination requires the MUS81 endonuclease. *Nat. Cell Biol.* **11**, 616–623
  54. Tarsounas, M., Muñoz, P., Claas, A., Smiraldi, P.G., Pittman, D.L., Blasco, M.A., and West, S.C. (2004) Telomere maintenance requires the RAD51D recombination/repair protein. *Cell* **117**, 337–347
  55. Saharia, A. and Stewart, S.A. (2009) FEN1 contributes to telomere stability in ALT-positive tumor cells. *Oncogene* **28**, 1162–1167
  56. Grudic, A., Jul-Larsen, A., Haring, S.J., Wold, M.S., Lønning, P.E., Bjerkvig, R., and Bøe, S.O. (2007) Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. *Nucleic Acids Res.* **35**, 7267–7278
  57. Fan, Q., Zhang, F., Barrett, B., Ren, K., and Andreassen, P.R. (2009) A role for monoubiquitinated FANCD2 at telomeres in ALT cells. *Nucleic Acids Res.* **37**, 1740–1754
  58. Jiang, W.Q., Zhong, Z.H., Nguyen, A., Henson, J.D., Toouli, C.D., Braithwaite, A.W., and Reddel, R.R. (2009) Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins. *J. Cell Biol.* **185**, 797–810
  59. De'jardin, J. and Kingston, R.E. (2009) Purification of proteins associated with specific genomic loci. *Cell* **136**, 175–186
  60. Perrem, K., Bryan, T.M., Englezou, A., Hackl, T., Moy, E.L., and Reddel, R.R. (1999) Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids. *Oncogene* **18**, 3383–3390
  61. Lundblad, V. and Blackburn, E.H. (1993) An alternative pathway for yeast telomere maintenance rescues est1-senescence. *Cell* **73**, 347–360
  62. Teng, S.C. and Zakian, V.A. (1999) Telomere-telomere recombination is an efficient bypass pathway for telomere maintenance in *Saccharomyces cerevisiae*. *Mol. Cell Biol.* **19**, 8083–8093
  63. Lin, C.Y., Chang, H.H., Wu, K.J., Tseng, S.F., Lin, C.C., Lin, C.P., and Teng, S.C. (2005) Extrachromosomal telomeric circles contribute to Rad52-, Rad50-, and polymerase delta-mediated telomere-telomere recombination in *Saccharomyces cerevisiae*. *Eukaryot. Cell* **4**, 327–336
  64. Natarajan, S., Groff-Vindman, C., and McEachern, M.J. (2003) Factors influencing the recombinational expansion and spread of telomeric tandem arrays in *Kluyveromyces lactis*. *Eukaryot. Cell* **2**, 1115–1127
  65. Natarajan, S. and McEachern, M.J. (2002) Recombinational telomere elongation promoted by DNA circles. *Mol. Cell Biol.* **22**, 4512–4521
  66. Niida, H., Shinkai, Y., Hande, M.P., Matsumoto, T., Takehara, S., Tachibana, M., Oshimura, M., Lansdorff, P.M., and Furuichi, Y. (2000) Telomere maintenance in telomerase-deficient mouse embryonic stem cells: characterization of an amplified telomeric DNA. *Mol. Cell Biol.* **20**, 4115–4127
  67. Chang, S., Khoo, C.M., Naylor, M.L., Maser, R.S., and DePinho, R.A. (2003) Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. *Genes Dev.* **17**, 88–100
  68. Gonzalo, S., Jaco, I., Fraga, M.F., Chen, T., Li, E., Esteller, M., and Blasco, M.A. (2006) DNA methyltransferases control telomere length and telomere recombination in mammalian cells. *Nat. Cell Biol.* **8**, 416–424
  69. Tilman, G., Lorient, A., Van Beneden, A., Arnoult, N., Londoño-Vallejo, J.A., De Smet, C., and Decottignies, A. (2009) Subtelomeric DNA hypomethylation is not required for telomeric sister chromatid exchanges in ALT cells. *Oncogene* **28**, 1682–1693
  70. Yankiwski, V., Marciniak, R.A., Guarente, L., and Neff, N.F. (2000) Nuclear structure in normal and Bloom syndrome cells. *Proc. Natl. Acad. Sci. USA* **97**, 5214–5219
  71. Wu, G., Jiang, X., Lee, W.H., and Chen, P.L. (2003) Assembly of functional ALT-associated promyelocytic leukemia bodies requires Nijmegen Breakage Syndrome 1. *Cancer Res.* **63**, 2589–2595
  72. Zhu, X.D., Niedernhofer, L., Kuster, B., Mann, M., Hoeijmakers, J.H., and de Lange, T. (2003) ERCC1/XPF removes the 3' overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes. *Mol. Cell* **12**, 1489–1498
  73. Moran-Jones, K., Wayman, L., Kennedy, D.D., Reddel, R.R., Sara, S., Snee, M.J., and Smith, R. (2005) hnRNP A2, a potential ssDNA/RNA molecular adapter at the telomere. *Nucleic Acids Res.* **33**, 486–496
  74. Zhu, X.D., Kuster, B., Mann, M., Petrini, J.H., and de Lange, T. (2000) Cell-cycle-regulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres. *Nat. Genet.* **25**, 347–352
  75. Dantzer, F., Giraud-Panis, M.J., Jaco, I., Amé, J.C., Schultz, I., Blasco, M., Koering, C.E., Gilson, E., Ménessier-de Murcia, J., de Murcia, G., and Schreiber, V. (2004) Functional interaction between poly(ADP-Ribose) polymerase 2 (PARP-2) and TRF2: PARP activity negatively regulates TRF2. *Mol. Cell Biol.* **24**, 1595–1607
  76. Silverman, J., Takai, H., Buonomo, S.B., Eisenhaber, F., and de Lange, T. (2004) Human Rif1, ortholog of a yeast telomeric protein, is regulated by ATM and 53BP1 and functions in the S-phase checkpoint. *Genes Dev.* **18**, 2108–2119
  77. Miyake, Y., Nakamura, M., Nabetani, A., Shimamura, S., Tamura, M., Yonehara, S., Saito, M., and Ishikawa, F. (2009) RPA-like mammalian Ctc1-Stn1-Ten1 complex binds to single-stranded DNA and protects telomeres independently of the Pot1 pathway. *Mol. Cell* **36**, 193–206
  78. Johnson, F.B., Marciniak, R.A., McVey, M., Stewart, S.A., Hahn, W.C., and Guarente, L. (2001) The *Saccharomyces cerevisiae* WRN homolog Sgs1p participates in telomere maintenance in cells lacking telomerase. *EMBO J.* **20**, 905–913
  79. Opreško, P.L., Otterlei, M., Graakjaer, J., Bruheim, P., Dawut, L., Kølvrå, S., May, A., Seidman, M.M., and Bohr, V.A. (2004) The Werner syndrome helicase and exonuclease cooperate to resolve telomeric D loops in a manner regulated by TRF1 and TRF2. *Mol. Cell* **14**, 763–774

